ZIPRASIDONE HYDROCHLORIDE CAPSULES 20 mg, Unit Dose Carton 40 Capsules, Rx only, Mfd. By: Dr. Red...
FDA Drug Recall #D-0893-2023 — Class I — May 31, 2023
Recall Summary
| Recall Number | D-0893-2023 |
| Classification | Class I — Serious risk |
| Date Initiated | May 31, 2023 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories |
| Location | La Vergne, TN |
| Product Type | Drugs |
| Quantity | unknown |
Product Description
ZIPRASIDONE HYDROCHLORIDE CAPSULES 20 mg, Unit Dose Carton 40 Capsules, Rx only, Mfd. By: Dr. Reddy's Laboratories Limited Bachupally-500 090 India, Distributed by: Major Pharmaceuticals Livonia, MI 48152 USA, NDC 0904-6269-08
Reason for Recall
Labeling: Label Mix-up: Unit Dose cartons labeled as Ziprasidone Hydrochloride Capsules, 20 mg were found to contain blister packages labeled as and containing Dronabinol Capsules, USP, 2.5 mg.
Distribution Pattern
Nationwide in the USA
Lot / Code Information
Lot: T04769 Exp. 2024/12
Other Recalls from The Harvard Drug Group LLC dba Major ...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0011-2026 | Class II | Major ChlorproMAZINE Hydrochloride Tablets, USP... | Sep 12, 2025 |
| D-0009-2026 | Class II | Major ChlorproMAZINE Hydrochloride Tablets, USP... | Sep 12, 2025 |
| D-0013-2026 | Class II | Major ChlorproMAZINE Hydrochloride Tablets, USP... | Sep 12, 2025 |
| D-0012-2026 | Class II | Major ChlorproMAZINE Hydrochloride Tablets, USP... | Sep 12, 2025 |
| D-0010-2026 | Class II | Major ChlorproMAZINE Hydrochloride Tablets, USP... | Sep 12, 2025 |
Frequently Asked Questions
Stop using the medication immediately and contact your pharmacist. A mislabeling recall can range from a minor technical error (wrong font size) to a serious mix-up where one drug is inside another drug's packaging. If you received a medication that looks or acts differently than expected, or if you experienced unexpected effects, tell your doctor immediately. The pharmacist can verify whether your specific lot is affected and provide a replacement. Report any adverse effects experienced to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.